Nilsson O S, Bauer H C, Brostrom L A
Department of Orthopaedic Surgery, Karolinska Institute and Hospital, Stockholm, Sweden.
J Orthop Res. 1990 Mar;8(2):199-204. doi: 10.1002/jor.1100080207.
The effect of the two antineoplastic drugs, Adriamycin and methotrexate, on orthotopic bone, and on the induction of experimental heterotopic bone in rats was analyzed. The drugs were administered as single injections: Adriamycin in s.c. doses of 0.5 and 2 mg/kg body weight and methotrexate i.v. 100 and 250 mg/kg body weight followed by leucovorin rescue after 2 h. A passing, but significant, decrease in body weights occurred in the methotrexate-treated animals, but not in those given Adriamycin. Analysis of the amount of heterotopic bone formed 4 weeks after induction by demineralized bone matrix revealed a 30-40% decrease in the groups treated with either of the antineoplastic agents, whereas orthotopic bone was unaffected. Six weeks after the treatment the net effect on the induced bone had decreased. The present study shows that the two antineoplastic drugs Adriamycin and methotrexate inhibit heterotopic new bone formation induced by demineralized bone matrix in rats to an equal extent, although their mode of action on the cellular level is entirely different, and that the inhibitory effect of a single treatment diminishes in the presence of a continuous inductive process.
分析了两种抗肿瘤药物阿霉素和甲氨蝶呤对大鼠原位骨以及诱导实验性异位骨形成的影响。药物均单次注射给药:阿霉素皮下注射剂量为0.5和2mg/kg体重,甲氨蝶呤静脉注射剂量为100和250mg/kg体重,2小时后给予亚叶酸钙解救。甲氨蝶呤治疗的动物体重出现短暂但显著的下降,而给予阿霉素的动物体重未下降。通过脱矿骨基质诱导4周后形成的异位骨量分析显示,两种抗肿瘤药物治疗组的异位骨量均减少了30 - 40%,而原位骨未受影响。治疗6周后,对诱导骨的净效应有所降低。本研究表明,两种抗肿瘤药物阿霉素和甲氨蝶呤对大鼠脱矿骨基质诱导的异位新骨形成的抑制程度相同,尽管它们在细胞水平上的作用方式完全不同,并且单次治疗的抑制作用在持续诱导过程中会减弱。